Document


 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 30, 2018
 
LANTHEUS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
001-36569
35-2318913
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
331 Treble Cove Road, North Billerica, MA
 
01862
(Address of principal executive offices)
 
(Zip Code)
Registrant’s telephone number, including area code: (978) 671-8001
Not Applicable
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company þ
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. þ
 
 
 





Item 2.02.
Results of Operations and Financial Condition.
On October 30, 2018, Lantheus Holdings, Inc. (the “Company”) announced via press release its financial results as of and for the three and nine months ended, September 30, 2018. A copy of that press release is being furnished as Exhibit 99.1 and is hereby incorporated by reference.
The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
 
Description
99.1*
 

*
Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
 





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LANTHEUS HOLDINGS, INC.
 
 
By:
/S/ Michael P. Duffy
Name:
Michael P. Duffy
Title:
General Counsel, Senior Vice President, Law and Public Policy, and Secretary


Date: October 30, 2018






EXHIBIT INDEX
 
Exhibit No.
 
Description
99.1*
 
*
Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.



Exhibit


Exhibit 99.1
https://cdn.kscope.io/a077352ff08788f60ca570f380e28753-lantheusa03.jpg
331 Treble Cove Road
North Billerica, MA 01862
800.362.2668
www.lantheus.com

Lantheus Holdings, Inc. Reports Third Quarter 2018 Financial Results

Worldwide revenues of $88.9 million for the third quarter, an increase of 11.2% over the prior year period

Net income for the third quarter of $9.3 million, or $0.24 per diluted share, an increase of 8.7% over the prior year period

EBITDA of $20.0 million and Adjusted EBITDA of $26.1 million for the third quarter, an increase of 17.9% and 15.5% over the prior year period, respectively

Company reaffirms full-year revenue and updates Adjusted EBITDA guidance


NORTH BILLERICA, Mass., October 30, 2018 - Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today reported financial results for its third quarter ended September 30, 2018.

The Company’s worldwide revenues for the third quarter of 2018 totaled $88.9 million, compared with $79.9 million for the third quarter of 2017. Net income for the third quarter of 2018 totaled $9.3 million, or $0.24 per diluted share, compared with $8.5 million, or $0.22 per diluted share, for the third quarter of 2017. The Company’s third quarter 2018 EBITDA was $20.0 million, or 22.5% of revenues, and its Adjusted EBITDA was $26.1 million, or 29.4% of revenues, as compared with 21.2%, and 28.3% of revenues for the third quarter of 2017, respectively.

“We delivered double-digit growth in both DEFINITY and TechneLite in the third quarter,” said Mary Anne Heino, President and CEO of Lantheus. “We continue to leverage our portfolio of products and capabilities to optimize growth and ensure the flexibility to respond to opportunities. As we consider investment strategies to expand and diversify our business, this robust financial performance further strengthens our balance sheet and ability to execute on initiatives.”

Outlook
The Company reaffirms its full-year 2018 worldwide revenue guidance range of $337 million to $342 million. The Company has increased its full-year 2018 guidance range for Adjusted EBITDA, as described in the GAAP to non-GAAP reconciliation provided later in this release, to $90 million to $93 million from previous guidance of $85 million to $90 million, a margin of 26.3% to 27.6% of anticipated worldwide revenues.

The Company’s guidance for worldwide revenues and Adjusted EBITDA are forward-looking statements. They are subject to various risks and uncertainties that could cause the Company’s actual results to differ materially from guidance. Forward-looking statements are not predictions of the Company’s actual performance. See the cautionary information about forward-looking statements in the “Safe-Harbor Statement” section of this press release.

Internet Posting of Information
The Company routinely posts information that may be important to investors in the “Investors” section of its website at http://www.lantheus.com/. The Company encourages investors and potential investors to consult its website regularly for important information about the Company.



Page 1 of 10




Conference Call and Webcast
As previously announced, the Company will host a conference call starting at 4:30 p.m. Eastern Time today. To access the live conference call via telephone, please dial 1-866-498-8390 (U.S. callers) or 1-678-509-7599 (international callers) and provide passcode 8386986. A live audio webcast of the call also will be available in the Investors section of the Company’s website at www.lantheus.com.

A replay of the audio webcast will be available in the Investors section of our website at www.lantheus.com approximately two hours after completion of the call and will be archived for 30 days.

The conference call will include a discussion of non-GAAP financial measures. Reference is made to the most directly comparable GAAP financial measures, the reconciliation of the differences between the two financial measures, and the other information included in this press release, our Form 8-K filed with the SEC today, or otherwise available in the Investor Relations section of our website located at www.lantheus.com.

The conference call may include forward-looking statements. See the cautionary information about forward-looking statements in the safe-harbor section of this press release.

About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.
Lantheus Holdings, Inc. is the parent company of LMI, a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, including the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. The Company is headquartered in North Billerica, Massachusetts with offices in Puerto Rico and Canada. For more information, visit www.lantheus.com.

Non-GAAP Financial Measures
The Company uses non-GAAP financial measures, such as revenues excluding the impact of foreign currency; adjusted operating income; adjusted net income and its line components; EBITDA; Adjusted EBITDA; adjusted net income per share - diluted; and free cash flow. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. The measures may exclude such items which may be highly variable, difficult to predict and of a size that could have substantial impact on the Company’s reported results of operations for a period. Management uses these and other non-GAAP measures internally for evaluation of the performance of the business, including the allocation of resources and the evaluation of results relative to employee performance compensation targets. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

This press release includes forward-looking non-GAAP guidance for 2018 Adjusted EBITDA. No reconciliation of this forward-looking non-GAAP guidance was included in this press release because, due to the high variability and difficulty in making accurate forecasts and projections of some of the excluded information and the fact that some of the excluded information is not readily ascertainable or accessible, the Company is unable to quantify certain amounts that would be required to be included in the most directly comparable GAAP financial measure without unreasonable efforts.

Safe Harbor for Forward-Looking and Cautionary Statements
This press release contains “forward-looking statements” as defined under U.S. federal securities laws, including statements about our 2018 outlook. Forward-looking statements may be identified by their use of terms such as anticipate, believe, confident, could, estimate, expect, intend, may, plan, predict, project, target, will and other similar terms. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward- looking statements. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements are discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q).

Page 2 of 10





Contact
Meara Murphy
978-671-8508
Director, Investor Relations and Corporate Communications
Lantheus Holdings, Inc.
- Tables Follow -


Page 3 of 10



Lantheus Holdings, Inc.
Consolidated Statements of Operations
(in thousands, except per share data – unaudited)
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Revenues
$
88,900

 
$
79,941

 
$
257,103

 
$
250,137

Cost of goods sold
44,015

 
41,414

 
126,063

 
125,901

Gross profit
44,885

 
38,527

 
131,040

 
124,236

Operating expenses
 
 
 
 
 
 
 
Sales and marketing
10,478

 
10,075

 
33,248

 
31,892

General and administrative
13,609

 
12,076

 
37,727

 
35,549

Research and development
4,316

 
3,554

 
12,520

 
14,149

Total operating expenses
28,403

 
25,705

 
83,495

 
81,590

Operating income
16,482

 
12,822

 
47,545

 
42,646

Interest expense
4,446

 
4,442

 
12,794

 
14,147

Loss on extinguishment of debt

 

 

 
2,161

Other income
(799
)
 
(908
)
 
(2,055
)
 
(2,037
)
Income before income taxes
12,835

 
9,288

 
36,806

 
28,375

Income tax expense
3,566

 
762

 
9,581

 
2,116

Net income
$
9,269

 
$
8,526

 
$
27,225

 
$
26,259

Net income per common share:
 
 
 
 
 
 
 
Basic
$
0.24

 
$
0.23

 
$
0.71

 
$
0.71

Diluted
$
0.24

 
$
0.22

 
$
0.69

 
$
0.67

Weighted-average common shares outstanding:
 
 
 
 
 
 
 
Basic
38,342

 
37,393

 
38,155

 
37,174

Diluted
39,402

 
39,121

 
39,467

 
38,971


Page 4 of 10



Lantheus Holdings, Inc.
Consolidated Segment Revenues Analysis
(in thousands – unaudited)
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
2017
Change
%
 
2018
2017
Change
%
United States
 
 
 
 
 
 
 
 
 
 
 
DEFINITY
$
42,472

 
$
36,901

 
15.1
 %
 
$
131,081

 
$
113,035

 
16.0
 %
TechneLite
19,374

 
22,621

 
(14.4
)%
 
56,780

 
69,150

 
(17.9
)%
Xenon
7,239

 
7,726

 
(6.3
)%
 
22,805

 
23,709

 
(3.8
)%
Other
1,170

 
2,331

 
(49.8
)%
 
5,163

 
12,812

 
(59.7
)%
Total United States
70,255

 
69,579

 
1.0
 %
 
215,829

 
218,706

 
(1.3
)%
International
 
 
 
 
 
 
 
 
 
 
 
DEFINITY
1,283

 
828

 
55.0
 %
 
3,427

 
2,534

 
35.2
 %
TechneLite
11,244

 
3,735

 
201.0
 %
 
18,711

 
10,750

 
74.1
 %
Xenon

 

 
 %
 

 
4

 
(100.0
)%
Other
6,118

 
5,799

 
5.5
 %
 
19,136

 
18,143

 
5.5
 %
Total International
18,645

 
10,362

 
79.9
 %
 
41,274

 
31,431

 
31.3
 %
Worldwide
 
 
 
 
 
 
 
 
 
 
 
DEFINITY
43,755

 
37,729

 
16.0
 %
 
134,508

 
115,569

 
16.4
 %
TechneLite
30,618

 
26,356

 
16.2
 %
 
75,491

 
79,900

 
(5.5
)%
Xenon
7,239

 
7,726

 
(6.3
)%
 
22,805

 
23,713

 
(3.8
)%
Other
7,288

 
8,130

 
(10.4
)%
 
24,299

 
30,955

 
(21.5
)%
Total Revenues
$
88,900

 
$
79,941

 
11.2
 %
 
$
257,103

 
$
250,137

 
2.8
 %

Page 5 of 10



Lantheus Holdings, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
(in thousands – unaudited)
 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
 
2018
 
2017
 
2018
 
2017
Operating income
 
$
16,482

 
$
12,822

 
$
47,545

 
$
42,646

Campus consolidation costs including depreciation
 
84

 
797

 
1,154

 
5,779

Offering and other costs
 

 
73

 

 
602

Non-recurring refinancing related fees
 

 

 

 
1,721

Adjusted operating income
 
$
16,566

 
$
13,692

 
$
48,699

 
$
50,748

Adjusted operating income, as a percentage of revenues
 
18.6
%
 
17.1
%
 
18.9
%
 
20.3
%


Page 6 of 10



Lantheus Holdings, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
(in thousands, except per share data – unaudited)
 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
 
2018
 
2017
 
2018
 
2017
Net income
 
$
9,269

 
$
8,526

 
$
27,225

 
$
26,259

Reconciling items impacting operating income:
 
 
 
 
 
 
 
 
Campus consolidation costs including depreciation
 
84

 
797

 
1,154

 
5,779

Offering and other costs
 

 
73

 

 
602

Non-recurring refinancing related fees
 

 

 

 
1,721

Reconciling items impacting non-operating expenses and income taxes:
 
 
 
 
 
 
 
 
Loss on debt extinguishment and retirement costs
 

 

 

 
2,161

Income tax effect of non-GAAP adjustments(a) (b)
 
(21
)
 
(220
)
 
(291
)
 
(2,591
)
Adjusted net income
 
$
9,332

 
$
9,176

 
$
28,088

 
$
33,931

Adjusted net income, as a percentage of revenues
 
10.5
%
 
11.5
%
 
10.9
%
 
13.6
%
 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
 
2018
 
2017
 
2018
 
2017
Net income per share - diluted
 
$
0.24

 
$
0.22

 
$
0.69

 
$
0.67

Reconciling items impacting operating income:
 
 
 
 
 
 
 
 
Campus consolidation costs including depreciation
 

 
0.02

 
0.03

 
0.15

Offering and other costs
 

 

 

 
0.02

Non-recurring refinancing related fees
 

 

 

 
0.04

Reconciling items impacting non-operating expenses and income taxes:
 
 
 
 
 
 
 
 
Loss on debt extinguishment and retirement costs
 

 

 

 
0.06

Tax effect of non-GAAP adjustments(a) (b)
 

 
(0.01
)
 
(0.01
)
 
(0.07
)
Adjusted net income per share - diluted
 
$
0.24

 
$
0.23

 
$
0.71

 
$
0.87

Weighted-average common shares outstanding - diluted
 
39,402

 
39,121

 
39,467

 
38,971

(a)
The income tax effect of the adjustments between GAAP net income and non-GAAP adjusted net income takes into account the tax treatment and related tax rate that apply to each adjustment in the applicable tax jurisdiction.
(b)
During the fourth quarter of 2017, we released the valuation allowance previously recorded against our domestic net deferred tax assets. As a result, we included the tax effect of non-GAAP adjustments starting in the fourth quarter of 2017. Presentation of 2017 Adjusted Net Income has been modified to allow better go-forward comparability by including the tax effect of non-GAAP reconciling items.

Page 7 of 10



Lantheus Holdings, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
(in thousands – unaudited)
 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
 
2018
 
2017
 
2018
 
2017
Net income
 
$
9,269

 
$
8,526

 
$
27,225

 
$
26,259

Interest expense, net
 
4,428

 
4,437

 
12,761

 
14,134

Income tax expense(a)
 
2,875

 
272

 
7,361

 
646

Depreciation
 
1,805

 
2,102

 
5,533

 
10,066

Amortization of intangible assets
 
1,650

 
1,646

 
5,011

 
4,953

EBITDA
 
20,027

 
16,983

 
57,891

 
56,058

Stock and incentive plan compensation
 
2,639

 
1,933

 
7,015

 
4,735

Asset write-off (b)
 
1,254

 
911

 
3,273

 
2,184

Severance and recruiting costs (c)
 
1,776

 
666

 
2,227

 
1,033

Offering and other costs (d)
 

 
73

 

 
602

Campus consolidation costs
 
84

 
408

 
1,154

 
1,101

Debt refinancing costs
 

 

 

 
1,721

Extinguishment of debt and debt retirement costs
 

 

 

 
2,161

New manufacturer costs (e)
 
334

 
1,639

 
1,301

 
3,616

Adjusted EBITDA
 
$
26,114

 
$
22,613

 
$
72,861

 
$
73,211

Adjusted EBITDA, as a percentage of revenues
 
29.4
%
 
28.3
%
 
28.3
%
 
29.3
%
(a)
Represents income tax expense, less tax indemnification income associated with Bristol-Myers Squibb.
(b)
Represents non-cash losses incurred associated with inventory and other write-offs of long-lived assets.
(c)
The amounts consist of severance and recruitment costs related to employees, executives and directors.
(d)
Represents offering costs incurred on behalf of certain shareholders pursuant to a registration rights agreement and other non-recurring costs.
(e)
Represents internal and external costs associated with establishing new manufacturing sources for our commercial and clinical candidate products.

Page 8 of 10



Lantheus Holdings, Inc.
Reconciliation of Free Cash Flow
(in thousands – unaudited)
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
2018
 
2017
Net cash provided by operating activities
$
24,277

 
$
15,600

 
$
43,887

 
$
41,691

Capital expenditures
(5,005
)
 
(3,288
)
 
(12,766
)
 
(11,589
)
Free cash flow
$
19,272

 
$
12,312

 
$
31,121

 
$
30,102


Page 9 of 10



Lantheus Holdings, Inc.
Condensed Consolidated Balance Sheets
(in thousands – unaudited)
 
September 30,
2018
 
December 31,
2017
Assets
 
 
 
Current assets
 
 
 
Cash and cash equivalents
$
104,584

 
$
76,290

Accounts receivable, net
47,135

 
40,259

Inventory
34,572

 
26,080

Other current assets
4,669

 
5,221

Total current assets
190,960

 
147,850

Property, plant & equipment, net
99,407

 
92,999

Intangibles, net
9,727

 
11,798

Goodwill
15,714

 
15,714

Deferred tax assets, net
79,358

 
87,010

Other long-term assets
29,652

 
28,487

Total assets
$
424,818

 
$
383,858

Liabilities and stockholders’ equity
 
 
 
Current liabilities
 
 
 
Current portion of long-term debt
$
2,750

 
$
2,750

Revolving line of credit

 

Accounts payable
20,363

 
17,464

Accrued expenses and other liabilities
31,464

 
26,536

Total current liabilities
54,577

 
46,750

Asset retirement obligations
11,282

 
10,412

Long-term debt, net
264,130

 
265,393

Other long-term liabilities
39,321

 
38,012

Total liabilities
369,310

 
360,567

Total stockholders’ equity
55,508

 
23,291

Total liabilities and stockholders’ equity
$
424,818

 
$
383,858

###

Page 10 of 10